Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial adhesion to gastric epithelial cells is the initial step whereby bacteria such as *Helicobacter pylori* attach to the mucosal lining of the stomach via specialized bacterial outer membrane proteins (adhesins) that recognize and bind to specific glycan structures on the host cell surface, including mucins and blood group antigens. Key bacterial adhesins involved include BabA (binding to Lewis b antigen), SabA (binding to sialyl-Lewis antigens), as well as several others (AlpA/B, HopQ, HopZ, OipA). This adhesion process is crucial for successful colonization, immune evasion, persistent infection, delivery of bacterial toxins (such as CagA), and subsequent disease pathogenesis (chronic gastritis, peptic ulcers, and gastric cancer). Disruption of this adhesion (by, e.g., probiotics, glycan analogs, or small molecules) has been explored as a therapeutic strategy, but no approved drugs specifically target this process as a unique molecular entity[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial adhesion to gastric epithelial cell.